Previous close | 2.0000 |
Open | 1.8500 |
Bid | 0.7500 |
Ask | 3.3000 |
Strike | 85.00 |
Expiry date | 2024-07-19 |
Day's range | 1.8500 - 2.0000 |
Contract range | N/A |
Volume | |
Open interest | 18 |
JUPITER, Fla., June 27, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration (FDA) for Ohtuvayre™ (ensifentrine). Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in more than 20 years. Ligand has earned a $5.8 million milestone payment upon FDA appro
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.